Why I’d Sell AstraZeneca plc And Buy Shire PLC

Shire PLC (LON: SHP) is a better bet than AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shireShire (LSE: SHP) and AstraZeneca (LSE: AZN) are two very different companies. On one hand, Shire is growing rapidly and has plenty of new drugs under development, which should drive sales growth.

On the other, Astra is suffering from falling sales and is trying hard to reinvigoration its drug development pipeline, in order to return to growth. 

Nevertheless, for many investors, Astra is the company of choice thanks to its attractive dividend yield of 3.9%. However, Shire’s potential for growth is not to be underestimated.

Niche market 

Shire has traditionally been dependent upon treatments for attention deficit hyperactivity disorder but the company is now becoming increasingly focused on rare disease treatment. A small but lucrative market. 

It’s Shire’s presence within this market, as well as the company’s history of growth that led management to claim that the group can double annual sales to $10bn by 2020. Of course, Shire is now in a better position to chase this growth than is has ever been before, after receiving $1.6bn merger break fee from AbbVie.

Even without this cash infusion it would appears as if Shire is well on its way to hitting this revenue target. Third quarter revenues rose almost a third to $1.6bn, beating estimates and hitting a record for the company. Excluding exceptional items, earnings per share rose to $2.10, or 129p for the nine months to 30 September, up 93% year on year.

City analysts currently expect the company to report earnings per share of 205p for full-year 2014, which puts the company on a forward P/E of 19.9.

Unfortunately, Shire does not offer much in the way of a dividend, so income seekers may be disappointed. The company’s shares support a dividend yield of 0.3% at present. Shire’s dividend payout is currently covered 13 times by earnings per share, leaving plenty of room for payout growth. There’s easily enough room for the company to hike its payout to 100p per share in the near future, a yield of 2.5% at present levels.

Far to go

As Shire’s growth explodes, Astra is struggling. The group’s sales and profits are expected to contract next year, with growth returning during 2016. Management believes that 2017 revenues will be broadly in line with 2013 revenues.

That being said, it remains to be seen if Astra can really generate this type of growth. There’s still plenty of work to do before the company’s experimental cancer treatments can be brought to market. And Astra is racing against the clock to develop its treatments, as many of the group’s peers are developing treatments with similar qualities. 

However, as Astra’s sales and earnings contract over the next two years, the company’s dividend, which is currently one of Astra’s most attractive qualities, will come under pressure.

Specifically, next year the company’s payout will only be covered 1.6 times by earnings per share. The year after the payout cover will fall to 1.4 times. If growth does not materialise then Astra could find itself paying out more than it can afford.

The bottom line

The best investors always look to the future, not the past. So, with this in mind Shire looks to be a better investment than Astra.

Shire has all the foundations in place to drive growth over the next few years. The treatment of rare diseases is a highly specialist and profitable business, as a result the company should be able to dominate the market. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »